Literature DB >> 10958792

Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin.

D L Persons1, E M Yazlovitskaya, J C Pelling.   

Abstract

The p53 tumor suppressor protein is a transcription factor that plays a major role in the DNA damage response. After DNA damage, p53 levels increase due primarily to stabilization of the protein. The molecular mechanisms leading to stabilization of p53 after DNA damage have not been completely elucidated. Recently we reported that cisplatin treatment activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and that inhibition of ERK1/2 resulted in enhanced sensitivity to cisplatin. In the present study, we examined the potential role of ERK1/2 activation in regulation of the p53 response to cisplatin. In the ovarian carcinoma cell line A2780, inhibition of ERK1/2 activation with the mitogen-activated protein kinase/ERK kinase 1 (MEK1) inhibitor PD98059 resulted in decreased p53 protein half-life and diminished accumulation of p53 protein during exposure to cisplatin. We also demonstrated that p53 protein co-immunoprecipitated with ERK1/2 protein and was phosphorylated by activated recombinant murine ERK2 in vitro. Furthermore, PD98059 decreased the phosphorylation of p53 at serine 15 during cisplatin exposure, suggesting that ERK1/2 mediates in part phosphorylation of p53 during the cisplatin DNA response. These results strongly suggest that cisplatin-induced ERK activation is an up-stream regulator of the p53 response to DNA damage caused by cisplatin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10958792     DOI: 10.1074/jbc.M004267200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  78 in total

1.  Tethering function of the caspase cleavage fragment of Golgi protein p115 promotes apoptosis via a p53-dependent pathway.

Authors:  Poh Choo How; Dennis Shields
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

2.  Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.

Authors:  Christine Billecke; Susan Finniss; Laura Tahash; Cathie Miller; Tom Mikkelsen; Nicholas P Farrell; Oliver Bögler
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

3.  Regulation of MDMX expression by mitogenic signaling.

Authors:  Daniele M Gilkes; Yu Pan; Domenico Coppola; Timothy Yeatman; Gary W Reuther; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

4.  Zinc induces expression of the BH3-only protein PUMA through p53 and ERK pathways in SH-SY5Y neuroblastoma cells.

Authors:  Hirokazu Hara; Tetsuro Kamiya; Tetsuo Adachi
Journal:  Neurochem Res       Date:  2009-02-25       Impact factor: 3.996

5.  ATM mediates interdependent activation of p53 and ERK through formation of a ternary complex with p-p53 and p-ERK in response to DNA damage.

Authors:  Jee-In Heo; Soo-Jin Oh; Yoon-Jung Kho; Jeong-Hyeon Kim; Hong-Joon Kang; Seong-Hoon Park; Hyun-Seok Kim; Jong-Yeon Shin; Min-Ju Kim; Minju Kim; Sung Chan Kim; Jae-Bong Park; Jaebong Kim; Jae-Yong Lee
Journal:  Mol Biol Rep       Date:  2012-05-11       Impact factor: 2.316

6.  Cytosolic phospholipase A2 as a molecular target for the radiosensitization of ovarian cancer.

Authors:  Rachael R Schulte; Amanda G Linkous; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Cancer Lett       Date:  2011-05-28       Impact factor: 8.679

7.  MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.

Authors:  Lingtao Jin; Jaemoo Chun; Chaoyun Pan; Dan Li; Ruiting Lin; Gina N Alesi; Xu Wang; Hee-Bum Kang; Lina Song; Dongsheng Wang; Guojing Zhang; Jun Fan; Titus J Boggon; Lu Zhou; Jeanne Kowalski; Cheng-Kui Qu; Conor E Steuer; Georgia Z Chen; Nabil F Saba; Lawrence H Boise; Taofeek K Owonikoko; Fadlo R Khuri; Kelly R Magliocca; Dong M Shin; Sagar Lonial; Sumin Kang
Journal:  Cancer Cell       Date:  2018-07-19       Impact factor: 31.743

8.  Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.

Authors:  Dannah R Miller; Cherng-Chyi Tzeng; Trey Farmer; Evan T Keller; Steve Caplan; Yu-Shuin Chen; Yeh-Long Chen; Ming-Fong Lin
Journal:  Cancer Lett       Date:  2018-08-03       Impact factor: 8.679

9.  Development of a full-length human protein production pipeline.

Authors:  Justin Saul; Brianne Petritis; Sujay Sau; Femina Rauf; Michael Gaskin; Benjamin Ober-Reynolds; Irina Mineyev; Mitch Magee; John Chaput; Ji Qiu; Joshua LaBaer
Journal:  Protein Sci       Date:  2014-06-02       Impact factor: 6.725

10.  Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.

Authors:  Elisabetta Donzelli; Maria Carfì; Mariarosaria Miloso; Alberto Strada; Stefania Galbiati; Martine Bayssas; Genevieve Griffon-Etienne; Guido Cavaletti; Maria Grazia Petruccioli; Giovanni Tredici
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.